Carlo Ballatore

List of Publications by Year
in descending order

69	5,613	117625	98798
papers	citations	34 h-index	67 g-index

76	76	76	7494
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Reviews Neuroscience, 2007, 8, 663-672.	10.2	1,866
2	Carboxylic Acid (Bio)Isosteres in Drug Design. ChemMedChem, 2013, 8, 385-395.	3.2	377
3	The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice. Journal of Neuroscience, 2012, 32, 3601-3611.	3.6	325
4	Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy. Journal of Neuroscience, 2010, 30, 13861-13866.	3.6	256
5	Structure Property Relationships of Carboxylic Acid Isosteres. Journal of Medicinal Chemistry, 2016, 59, 3183-3203.	6.4	189
6	Targeting Heat Shock Proteins on Cancer Cells:Â Selection, Characterization, and Cell-Penetrating Properties of a Peptidic GRP78 Ligandâ€. Biochemistry, 2006, 45, 9434-9444.	2.5	172
7	Microtubule Stabilizing Agents as Potential Treatment for Alzheimerâ€™s Disease and Related Neurodegenerative Tauopathies. Journal of Medicinal Chemistry, 2012, 55, 8979-8996.	6.4	151
8	The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. Pharmacological Research, 2011, 63, 341-351.	7.1	135
9	Aminothienopyridazines and Methylene Blue Affect Tau Fibrillization via Cysteine Oxidation. Journal of Biological Chemistry, 2013, 288, 11024-11037.	3.4	128
10	Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. Communications Biology, 2022, 5, 169.	4.4	118
11	Identification of Aminothienopyridazine Inhibitors of Tau Assembly by Quantitative High-Throughput Screening. Biochemistry, 2009, 48, 7732-7745.	2.5	101
12	High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochemical and Biophysical Research Communications, 2007, 358, 1-6.	2.1	97
13	Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease. Bioorganic and Medicinal Chemistry, 2014, 22, 5040-5049.	3.0	87
14	Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimerâ€™s Disease and Related Tauopathies. Journal of Medicinal Chemistry, 2014, 57, 6116-6127.	6.4	84
15	Tau-directed drug discovery for Alzheimer's disease and related tauopathies: A focus on tau assembly inhibitors. Experimental Neurology, 2010, 223, 304-310.	4.1	81
16	The Presence of Substituents on the Aryl Moiety of the Aryl Phosphoramidate Derivative of d4T Enhances Anti-HIV Efficacy in Cell Culture:â€‰ A Structureâ€“Activity Relationship. Journal of Medicinal Chemistry, 1999, 42, 393-399.	6.4	80
17	Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs. Neurobiology of Disease, 2017, 105, 328-335.	4.4	74
18	1,2,4-Triazolo[1,5-a]pyrimidines in drug design. European Journal of Medicinal Chemistry, 2019, 165, 332-346.	5.5	68

#	Article	IF	Citations
19	Design and Synthesis of Lipophilic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture:â€‰ Structural Determinants for in Vitro Activity and QSAR. Journal of Medicinal Chemistry, 1999, 42, 4122-4128.	6.4	61
20	Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1053-1056.	2.2	60
21	Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimers Disease and Related Tauopathies. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 432-450.	2.5	58
22	Altered microtubule dynamics and vesicular transport in mouse and human MeCP2-deficient astrocytes. Human Molecular Genetics, 2016, 25, 146-157.	2.9	53
23	AÎ²-mediated spine changes in the hippocampus are microtubule-dependent and can be reversed by a subnanomolar concentration of the microtubule-stabilizing agent epothilone D. Neuropharmacology, 2016, 105, 84-95.	4.1	48
24	Discovery of Brain-Penetrant, Orally Bioavailable Aminothienopyridazine Inhibitors of Tau Aggregation. Journal of Medicinal Chemistry, 2010, 53, 3739-3747.	6.4	47
25	Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy. Acta Neuropathologica Communications, 2016, 4, 106.	5.2	45
26	Region-specific dendritic simplification induced by AÎ², mediated by tau via dysregulation of microtubule dynamics: a mechanistic distinct event from other neurodegenerative processes. Molecular Neurodegeneration, 2015, 10, 60.	10.8	44
27	Evaluation of logÂP, pKa, and logÂD predictions from the SAMPL7 blind challenge. Journal of Computer-Aided Molecular Design, 2021, 35, 771-802.	2.9	42
28	Solid phase synthesis of 2-aminobenzothiazoles. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 644-648.	2.2	41
29	Modulation of Protein-Protein Interactions as a Therapeutic Strategy for the Treatment of Neurodegenerative Tauopathies. Current Topics in Medicinal Chemistry, 2011, 11, 317-330.	2.1	40
30	Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimerâ€™s and Other Neurodegenerative Diseases. Journal of Medicinal Chemistry, 2017, 60, 5120-5145.	6.4	40
31	Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochemical Society Transactions, 2012, 40, 661-666.	3.4	39
32	Design, Synthesis, and Biological Evaluation of 1-Phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as New Glycogen Synthase Kinase-3Î² Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 10066-10078.	6.4	39
33	Separation of individual antiviral nucleotide prodrugs from synthetic mixtures using cross-reactivity of a molecularly imprinted stationary phase. Analytica Chimica Acta, 2001, 435, 107-113.	5.4	35
34	Cyclopentane-1,3-dione: A Novel Isostere for the Carboxylic Acid Functional Group. Application to the Design of Potent Thromboxane (A2) Receptor Antagonists. Journal of Medicinal Chemistry, 2011, 54, 6969-6983.	6.4	35
35	MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. ACS Medicinal Chemistry Letters, 2013, 4, 886-889.	2.8	33
36	Evaluation of Oxetan-3-ol, Thietan-3-ol, and Derivatives Thereof as Bioisosteres of the Carboxylic Acid Functional Group. ACS Medicinal Chemistry Letters, 2017, 8, 864-868.	2.8	32

#	Article	IF	Citations
37	Pharmacokinetic, pharmacodynamic and metabolic characterization of a brain retentive microtubule (MT)-stabilizing triazolopyrimidine. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4980-4982.	2.2	31
38	Aminothienopyridazine inhibitors of tau aggregation: Evaluation of structureâ€“activity relationship leads to selection of candidates with desirable in vivo properties. Bioorganic and Medicinal Chemistry, 2012, 20, 4451-4461.	3.0	29
39	A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model. Molecular Neurodegeneration, 2018, 13, 59.	10.8	27
40	Rational design, synthesis, and evaluation of uncharged, â€œsmartâ€•bis-oxime antidotes of organophosphate-inhibited human acetylcholinesterase. Journal of Biological Chemistry, 2020, 295, 4079-4092.	3.4	24
41	Brain-Penetrant Tetrahydronaphthalene Thromboxane A2-Prostanoid (TP) Receptor Antagonists as Prototype Therapeutics for Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2012, 3, 928-940.	3.5	22
42	Kinase-mediated trapping of bi-functional conjugates of paclitaxel or vinblastine with thymidine in cancer cells. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5194-5198.	2.2	21
43	Design, synthesis and evaluation of photoactivatable derivatives of microtubule (MT)-active [1,2,4]triazolo[1,5-a]pyrimidines. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2180-2183.	2.2	21
44	Non-Naturally Occurring Small Molecule Microtubule-Stabilizing Agents: A Potential Tactic for CNS-Directed Therapies. ACS Chemical Neuroscience, 2017, 8, 5-7.	3.5	20
45	Structure property relationships of N-acylsulfonamides and related bioisosteres. European Journal of Medicinal Chemistry, 2021, 218, 113399.	5.5	20
46	Paclitaxel C-10 carbamates: Potential candidates for the treatment of neurodegenerative tauopathies. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3642-3646.	2.2	19
47	Brainâ€Penetrant Triazolopyrimidine and Phenylpyrimidine Microtubule Stabilizers as Potential Leads to Treat Human African Trypanosomiasis. ChemMedChem, 2018, 13, 1751-1754.	3.2	19
48	Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant. ACS Omega, 2019, 4, 16999-17008.	3.5	19
49	Evaluation of the Structureâ€“Activity Relationship of Microtubule-Targeting 1,2,4-Triazolo[1,5-a]pyrimidines Identifies New Candidates for Neurodegenerative Tauopathies. Journal of Medicinal Chemistry, 2021, 64, 1073-1102.	6.4	17
50	Enhancing the aqueous solubility of d4T-based phosphoramidate prodrugs. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 381-384.	2.2	14
51	Simple mono-derivatisation of the aryl moiety of D4A and DDA-based phosphoramidate prodrugs significantly enhances their anti-HIV potency in cell culture. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2555-2560.	2.2	12
52	Phosphoramidate Derivatives of Stavudine as Inhibitors of HIV: Unnatural Amino Acids May Substitute for Alanine. Antiviral Chemistry and Chemotherapy, 2000, 11, 111-116.	0.6	11
53	In situ bloodâ€“brain barrier permeability of a C-10 paclitaxel carbamate. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 6119-6121.	2.2	11
54	Aminothienopyridazines as imaging probes of tau pathology: a patent evaluation of WO2013090497. Expert Opinion on Therapeutic Patents, 2014, 24, 355-360.	5.0	11

#	Article	IF	Citations
55	Correction of microtubule defects within AÎ² plaqueâ€associated dystrophic axons results in lowered AÎ² release and plaque deposition. Alzheimer's and Dementia, 2020, 16, 1345-1357.	0.8	11
56	Lactate cannot substitute for alanine in D4T-based anti-HIV nucleotide prodrugs-despite efficient esterase-mediated hydrolysis. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 2949-2954.	2.2	9
57	Evaluation of the cyclopentane-1,2-dione as a potential bio-isostere of the carboxylic acid functional group. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4171-4175.	2.2	9
58	A facile route to paclitaxel C-10 carbamates. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2477-2480.	2.2	8
59	The design, synthesis, and evaluation of two universal doxorubicin-linkers: Preparation of conjugates that retain topoisomerase II activity. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 104-107.	2.2	8
60	Inhibition of the HEG1â€“KRIT1 interaction increases KLF4 and KLF2 expression in endothelial cells. FASEB BioAdvances, 2021, 3, 334-355.	2.4	8
61	Potent, Long-Acting Cyclopentane-1,3-Dione Thromboxane (A₂)-Receptor Antagonists. ACS Medicinal Chemistry Letters, 2014, 5, 1015-1020.	2.8	6
62	Congeners Derived from Microtubule-Active Phenylpyrimidines Produce a Potent and Long-Lasting Paralysis of Schistosoma mansoni In Vitro. ACS Infectious Diseases, 2021, 7, 1089-1103.	3.8	6
63	Microtubule-Stabilizing Agents for Alzheimerâ€™s and Other Tauopathies. Topics in Medicinal Chemistry, 2016, , 159-179.	0.8	5
64	New Heights for ProTides?. Journal of Medicinal Chemistry, 2021, 64, 16422-16424.	6.4	4
65	92 Ara-A-5â€²-phenyl methoxy alaninyl phosphate as a prodrug of the adenine arabinoside -monophosphate: synthesis and anti viral evaluation. Antiviral Research, 2000, 46, A63.	4.1	2
66	Microtubule Stabilization. , 2016, , 305-326.		2
67	An In Situ Pig Liver Esterase Assay as a Useful Predictive Tool for the Likely In Vitro Anti Viral Activity of Phosphoramidate Pro-Drugs. Nucleosides & Nucleotides, 1999, 18, 967-969.	0.5	1
68	Thietanes and derivatives thereof in medicinal chemistry.. Current Topics in Medicinal Chemistry, 2022, 22, .	2.1	1
69	Alzheimerâ€™s Disease Drug Discovery in Academia: From High-Throughput Screening to In Vivo Testing. , 2022, , 34-44.		0